Schwarz is currently compiling the data from three separate rotigotine trials--two on early stage patients and one on late-stage patients--and the company expects to file for U.S. Food and Drug Administration approval by this fall.
This week, the Police Federation, which represents 125, 000 rank and file officers, warned ministers that they are planning to stage mass protest rallies.
But late-stage trials presented here at the annual meeting of the American Heart Association were promising enough that Acorn plans to file for marketing approval with the U.S. Food and Drug Administration by Dec. 10, with hopes of a decision in 2005.